Abstracts tagged "rheumatoid arthritis"

Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Matthew Wright¹, Mette Kiel Smed², J Lee Nelson³, Jørn Olsen⁴, Merete Hetland⁵, Vibeke Zoffmann² and Damini Jawaheer⁶, ¹UCSF Children's Hospital Oakland Research Institute, Oakland, CA, ²The Juliane Marie Center, Copenhagen, Denmark, ³Fred Hutchinson Cancer Res Ctr and U of WA, Seattle, WA, ⁴Aarhus University Hospital, Aarhus, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶UCSF Benioff Children's Hospital Oakland Research Institute, Oakland, CA
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…
Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Balázs Juhász¹, Katalin Gulyás¹, Ágnes Horváth¹, Edit Végh¹, Anita Pusztai², Ágnes Szentpétery³, Zsófia Pethő¹, Nóra Bodnár¹, Attila Hamar¹, Levente Bodoki¹, Harjit Bhattoa¹, Éva Szekanecz¹, Katalin Hodosi¹, Andrea Domján¹, Szilvia Szamosi¹, Csaba Horváth⁴, Sándor Szántó¹, Gabriella Szűcs¹, Hennie Raterman⁵, Oliver FitzGerald⁶ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Semmelweis University, Budapest, Hungary, ⁵Northwest Clinics, Alkmaar, Netherlands, ⁶Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…
Abstract Number: 0152 • ACR Convergence 2020
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Swathi Reddy¹, Aricca Van Citters², Rashmi Arora¹, Kyawt Shwin¹, Lisa Johnson², Jabeen Ahmad², Guy Eakin³, Eugene Nelson², Andreas Reimold¹ and Salahuddin Kazi¹, ¹Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ²The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, ³Arthritis Foundation, Atlanta, GA
Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
Abstract Number: 0187 • ACR Convergence 2020
Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C Keystone⁸, Diane Tin⁹, Carter Thorne⁹, Janet Pope¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹Hospital for Special Surgery, New York, NY, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Persistent pain can occur in early RA patients, despite improvement in synovitis and may be due to coexisting non-articular pain (NAP). Though NAP is…
Abstract Number: 0203 • ACR Convergence 2020
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use
Tatsuya Atsumi¹, Nami Okamoto², Nobunori Takahashi³, Naoto Tamura⁴, Atsuo Nakajima⁵, Ayako Nakajima⁶, Takao Fujii⁷, Hiroaki Matsuno⁸, Yuko Takahashi⁹, Fumie Inui⁹, Naoto Tsujimoto⁹, Atsushi Nishikawa⁹, Taeko Ishii⁹, Tsutomu Takeuchi¹⁰, Masataka Kuwana¹¹ and Michiaki Takagi¹², ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ²Department of Rheumatology and Allergy of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan, ³Department of Orthopaedics/Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ⁵Ueno Touseki Clinic, Kitasaku District, Nagano, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu, Mie, Japan, ⁷Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Wakayama, Japan, ⁸Matsuno Clinic for Rheumatic Diseases, Toyama, Toyama, Japan, ⁹Eli Lilly, Kobe, Hyogo, Japan, ¹⁰Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ¹²Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Yamagata, Japan
Background/Purpose: To evaluate the safety of baricitinib in rheumatoid arthritis (RA) patients in clinical use.Methods: An all-case post-marketing study of baricitinib, started in September 2017,…
Abstract Number: 0219 • ACR Convergence 2020
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Raquel Dos-Santos¹, Sytske Anne Bergstra², J. M. Maassen², Thomas Huizinga² and CF Allaart², ¹Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…
Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, NooRi Han⁹ and HoJae Lee⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…
Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Julia Dupont¹, Gregory Guernec², Yannick Degboé³, Frédéric Lioté⁴, Olivier Vittecoq⁵, Arnaud Constantin⁶ and Adeline Ruyssen Witrand⁷, ¹University Hospital of Thoulouse, Toulouse, ²Inserm UMR 1027, TOULOUSE CEDEX 9, France, ³University Hospital of Toulouse, Toulouse, ⁴AP-HP, Paris, France, ⁵University Hospital of Rouen, Rouen, France, ⁶Rheumatology Department, Toulouse University Hospital, Toulouse, France, ⁷Rheumatology center, University Hospital of Toulouse, Inserm 1027, University Paul Sabatier, Toulouse, France, Toulouse, France
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…
Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Cesar Galan¹, Alan Puric², Guy Cozzi², Michele Hamburger³, Elisea Avalos-Reyes⁴ and Kjel Johnson¹, ¹CVS Health, Lincoln, RI, ²CVS Health, Northbrook, IL, ³Frances Hamburger Institute, Hauppauge, NY, ⁴CVS Health, Irving, TX
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
Abstract Number: 0745 • ACR Convergence 2020
Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment
Maya Breitman¹, Tracey Bonfield², Arnold Caplan³, Hillard Lazarus⁴, Maricela Haghiac⁵, Jane Reese⁶ and Nora Singer¹, ¹The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ²National Center of Regenerative Medicine Case Western Reserve University School of Medicine, Cleveland, OH, ³Skeletal Research Center Case Western Reserve University School of Medicine, Cleveland, OH, ⁴Case Western Reserve University School of Medicine, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Sero-positive rheumatoid arthritis (RA) is a chronic autoimmune disease that without effective treatment, leads to joint damage and disability. Not all patients respond to…
Abstract Number: 0762 • ACR Convergence 2020
Anti-Protein-Arginine Deiminase (PAD) 1 IgG Is a Promising Novel Autoantigen in Rheumatoid Arthritis (RA) and Increases Diagnostic Performance in Combination with Anti-PAD4 IgG Using a Composite Biomarker Score
Marcos Lopez-Hoyos¹, Chelsea Bentow², Andy Ishii², Laura Martinez-Prat³ and Michael Mahler², ¹Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Research and Development, Inova Diagnostics, Barcelona, Spain
Background/Purpose: Over the past years, novel biomarkers have been identified in the sera of rheumatoid arthritis (RA) patients, including autoantibodies to the protein-arginine deiminase (PAD)…
Abstract Number: 0779 • ACR Convergence 2020
Antibody Responses to Epstein-Barr Virus Are Altered in the Pre-Clinical Period of Rheumatoid Arthritis
Sabrina Fechtner¹, Heather Berens², Elizabeth Bemis³, M Kristen Demoruelle², Carla J. Guthridge⁴, John Harley⁵, Judith James⁶, Jess Edison⁷, Kevin D. Deane⁸, Jill Norris⁹ and V. Michael Holers², ¹University of Colorado, Aurora, CO, ²University of Colorado, Denver, CO, ³Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, ⁷Walter Reed National Military Medical Center, Bethesda, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Colorado School of Public Health, Aurora, CO
Background/Purpose: Viral infections, including infection with Epstein-Barr virus (EBV), have been suggested as environmental risk factors for rheumatoid arthritis (RA). EBV infections are known to…
Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Hayley Carr¹, Ilfita Sahbudin¹, Mark Maybury¹, Bernard Dyke², Jason Turner³, Nicola Gullick⁴, Karim Raza⁵, Dagmar Scheel-Toellner¹ and Andrew Filer¹, ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
Abstract Number: 0812 • ACR Convergence 2020
Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Simon Helfgott¹, Janna Radtchenko², Nehad Soloman³, Kent Kwas Huston⁴, Jasvinder Singh⁵ and Colin Edgerton⁶, ¹BWH- HMS, Boston, MA, ²Trio Health, Louisville, CO, ³Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁴Kansas City Physician Partners, Kansas City, MO, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Biologics have revolutionized the treatment of autoimmune diseases, though costs and payer restrictions have limited who are treated and when these agents are used. …

1
2
3
…
58
Next Page »